Cytokinetics reported $-167.09M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Arca Biopharma USD -36.43M 2M Mar/2026
Bayer EUR 129M 698M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cytokinetics USD -167.09M 12.08M Sep/2026
Eisai JPY 16.7B 8.03B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 268.42M 20.01M Sep/2026
Geron USD 5.73M 18.38M Sep/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 392M Sep/2026
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026